Effect of irbesartan on progression of chronic kidney disease

Effect of irbesartan on progression of chronic kidney disease - Effect of irbesartan on progression of chronic kidney disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006609

Enrollment

Registered

2011-10-25

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Blood and urine sampling at 4,8 and 24 weeks after admistration of irbesartan. Volume of blood sampling is 6ml.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Chronic kidney disease who were treated at Department of nephrology, Tsukuba University Hosputal, Ibaraki, Japan. 2)Patients who are prescribed irbesartan 3) Patients who gave written infromed consent

Exclusion criteria

Exclusion criteria: 1) Patients with hypertensive crisis 2) Pregant or possible pregnant patients 3)Bilateral renal artery stenosis 4)anemia (Hb<8g/dl) 5)liver dysfunction (ALT>200IU/L) 6)modelate renal dysfunction(eGFR<40ml/min) 7)hyperkalemia (serum potassium conc. >6mEq/L) 8)Allergic reaction to irbesartan

Design outcomes

Primary

Measure	Time frame
1. Change of blood pressure 2. Change of urinary albumin and protein excretion	—

Secondary

Measure	Time frame
Change of serum parameters related to metabolic syndrome (insulin, adiponectin, leptin, hsCRP, TNF alfa, IL-6)	—

Countries

Japan

Contacts

Public ContactShuichi Tsuruoka

University of Tsukuba Nephrology

029-853-3202

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026